TickerFacts.

CASI Pharmaceuticals, Inc. (CASIF): Gross Profit

Annual figures by period end, from SEC filings.

$10.08M
Year ended 2025-12-31
-28.3%
3-year compound annual growth
+12.3%
5-year compound annual growth
$27.28M2020-12-31: $5.63M2021-12-31: $17.61M2022-12-31: $27.28M2023-12-31: $20.05M2024-12-31: $11.15M2025-12-31: $10.08M$10.08M
2020-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$10.08M-9.6%2026-05-15, From 2025-01-01
2024-12-31$11.15M-44.4%2026-05-15, From 2024-01-01
2023-12-31$20.05M-26.5%2026-05-15, From 2023-01-01
2022-12-31$27.28M+54.9%2025-03-31, From 2022-01-01
2021-12-31$17.61M+212.6%2024-03-28, From 2021-01-01
2020-12-31$5.63Mn/a2023-04-26, From 2020-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$10.08M-9.6%
Evofem Biosciences, Inc. (EVFM)2025-12-31$15.57M+0.2%
Celularity Inc (CELU)2025-12-31$6.48M-83.5%
uniQure N.V. (QURE)2025-12-31$14.41Mn/a
Pyxis Oncology, Inc. (PYXS)2025-12-31$11.47Mn/a
CV Sciences, Inc. (CVSI)2025-12-31$6.75M-5.8%
Zomedica Corp. (ZOMDF)2025-12-31$21.68M+13.6%
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$6.47M+177.7%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$11.60M-25.0%

Compare CASIF, EVFM, CELU, QURE side by side · Screen every company in Pharmaceutical Preparations ↗